Journal Watch · Nature Communications · 2026

BCAT1 inhibits crotonate-related epigenetic modulation of metabolic genes in tumor-associated macrophages to counter immunosuppression.

In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1<sup>+</sup> macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

Zhang W, Liang S, Han S et al.Nature Communications3 min readPharma relevance 60/100

DOI: 10.1038/s41467-026-72814-wPMID: 42115179Study type: preclinical (animal / model) study

TL;DR

In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1<sup>+</sup> macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

Key findings

  • In HCC mouse models, BCAT1-deficient TAMs aggravate tumor burden and suppress CD8<sup>+</sup> T cell-mediated antitumor immunity, while myeloid-specific BCAT1 overexpression or adoptive transfer of BCAT1<sup>+</sup> macrophages stimulates the antitumor immune response and improves anti-PD1 therapy responses.
  • In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1<sup>+</sup> macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

What they did

Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs constraining tumor progression. Compared with wild-type TAMs, BCAT1-deficient TAMs have increased intracellular crotonate, as well as enhanced histone H3 lysine 14 crotonylation, upregulated lipid metabolism genes and an immunosuppressive phenotype.

Full abstract (original)

Background: The heterogeneous and immunosuppressive tumor microenvironment (TME) in hepatocellular carcinoma (HCC) contributes to poor immunotherapy responses. Tumor-associated macrophages (TAM) are central to the immunosuppressive TME, but how metabolic programs regulate TAM pro-tumorigenic functions remain incompletely understood.

What they did: Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs constraining tumor progression. Compared with wild-type TAMs, BCAT1-deficient TAMs have increased intracellular crotonate, as well as enhanced histone H3 lysine 14 crotonylation, upregulated lipid metabolism genes and an immunosuppressive phenotype.

Results & conclusions: In HCC mouse models, BCAT1-deficient TAMs aggravate tumor burden and suppress CD8<sup>+</sup> T cell-mediated antitumor immunity, while myeloid-specific BCAT1 overexpression or adoptive transfer of BCAT1<sup>+</sup> macrophages stimulates the antitumor immune response and improves anti-PD1 therapy responses. In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1<sup>+</sup> macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-72814-w · PubMed 42115179.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1<sup>+</sup> macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs constraining tumor progression.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-72814-w. PubMed ID: 42115179. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang W, Liang S, Han S et al.. BCAT1 inhibits crotonate-related epigenetic modulation of metabolic genes in tumor-associated macrophages to counter immunosuppression.. Nature Communications (2026). DOI: 10.1038/s41467-026-72814-w.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/bcat1-inhibits-crotonate-related-epigenetic-modulation-of-metabolic-gene-72814w/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides